zxclear

zxclear

[KR-바이오] 08/06 Korea Market Insights

삼성바이오로직스호재 As a senior equity analyst, I evaluate Samsung Biologics’ recent performance as a demonstration of robust fundamental growth. The company reported (record-breaking Q2 operating profit) of 586.4 billion KRW alongside strong revenues of 1.32 trillion KRW. Despite intensifying top-line…